New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma

Lahat, Guy; Tuvin, Daniel; Wei, Caimiao; Anaya, Daniel A.; Bekele, B. Nebiyou; Lazar, Alexander J.; Pisters, Peter W.T.; Lev, Dina; Pollock, Raphael E.

doi:10.1245/s10434-008-9970-6

Cited by 135 publications

(88 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To assess the impact of both SNPs on patient outcomes, Cox multivariate regression analysis was performed, adjusting for known prognostic factors of STS: tumor stage, resection type (R-status), and gender (20,21). Interestingly, the sarcoma patients harboring the alleles of the YWHAQ and CD44 SNPs, which in the NCI60 analysis were associated with weaker growth responses to chemotherapeutics, associated with poorer overall survival.…”

Section: Resultsmentioning

confidence: 99%

Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3τ and CD44 That Affect Sarcoma Incidence and Survival

et al. 2010

View full text Add to dashboard Cite

The p53 regulatory network responds to cellular stresses by initiating processes such as cell cycle arrest and apoptosis. These responses inhibit cellular transformation and mediate the response to many forms of cancer therapies. Functional variants in the genes comprising this network could help identify individuals at greater risk for cancer and patients with poorer responses to therapies, but few such variants have been identified as yet. We use the NCI60 human tumor cell line anticancer drug screen in a scan of single nucleotide polymorphisms (SNP) in 142 p53 stress response genes and identify 7 SNPs that exhibit allelic differences in cellular responses to a large panel of cytotoxic chemotherapeutic agents. The greatest differences are observed for SNPs in 14-3-3τ (YWHAQ; rs6734469, P = 5.6 × 10 −47 ) and CD44 (rs187115, P = 8

show abstract

Section: Resultsmentioning

confidence: 99%

Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3τ and CD44 That Affect Sarcoma Incidence and Survival

et al. 2010

View full text Add to dashboard Cite

show abstract

“…El abordaje de este tipo de tumores implica la necesidad de un estudio completo para definir la etiología del mismo (Lahat et al 2008). En el caso que se reporta, la presentación clínica insidiosa se asocia a la dificultad diagnóstica inherente; pocos fueron los síntomas relacionados con el efecto de masa que provocó el tumor en la paciente, se trató en sí de un hallazgo incidental.…”

Section: Discussionunclassified

Liposarcoma retroperitoneal gigante con compromiso renal izquierdo, reporte de un caso en el hospital “San Francisco de Quito”

Donoso¹,

Unda²,

Angos³

et al. 2016

REMCB

View full text Add to dashboard Cite

Los liposarcomas localizados en el retroperitoneo son por lo general lesiones de grado bajo e intermedio. La sintomatología predominante está relacionada con el efecto de masa. Dentro de los estudios de imagen, la tomografía simple y contrastada ha mostrado una adecuada sensibilidad. La terapia quirúrgica es la única opción que ofrece potencialmente beneficios curativos cuando se realiza resección completa con márgenes libres. El punto central de este estudio fue una paciente de 40 años, cuyo motivo de consulta fue prurito vaginal, dolor abdominal leve en hipogastrio y dispareunia tratada inicialmente por vaginosis a repetición. Al persistir dolor abdominal se solicita tomografía que evidencia masa hipodensa en región retroperitoneal que envuelve al riñón y al sistema pielocalicial del lado izquierdo. Se realizó laparotomía previa colocación de catéter doble J: el procedimiento fue excéresis de masa retroperitoneal más nefrectomía izquierda. Histopatología reportó liposarcoma de grado bajo con bordes de resección libres. Al momento, los controles tomográficos son negativos para recidivas. El tratamiento quirúrgico radical de los tumores de partes blandas ha mostrado un resultado favorable, en este caso, el resultado fue similar a los de estudios realizados de excéresis radical. La detección oportuna y el manejo multidisciplinario pueden ofrecer una terapia curativa.

show abstract

“…Biomarkers which can predict the high-risk patients are very important, because such biomarkers may be a useful indicator for determining whether adjuvant therapeutic modalities such as irradiation and chemotherapy should be performed. In MFH, the tumor size, tumor location, microscopic tumor necrosis and histologic grade have been shown to be important prognostic factors (27,30,35,36). Some of these factors are incorporated into staging systems that form the basis for decision making regarding adjuvant therapy and follow-up.…”

Section: A Discussionmentioning

confidence: 99%

The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas

Niimi

Matsumine²,

Iino³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. The human homologue of Drosophila disc large tumor suppressor protein (hDlg) is one of the proteins known to act cooperatively in regulating cell polarity and proliferation, suggesting an important connection between epithelial organization and cellular growth control. An abnormal expression of hDlg has been reported in several cancer types. However, the expression of hDlg in soft-tissue sarcomas has not yet been reported. We examined the expression of hDlg immunohistochemically in 46 specimens of malignant fibrous histiocytoma (MFH). The expression of hDlg was negative in 19 specimens, weak in 4, moderate in 16, and strong in 7. The patients with a weak or negative expression of hDlg had a significantly shorter metastasis-free survival rate and disease-free survival rate in comparison with those with a strong or moderate expression in both univariate analysis (p=0.0287 and 0.0237, respectively; log-rank test) and multivariate analysis (p=0.0087 and 0.0126, respectively; Cox proportional hazards regression model). Moreover, the patients with a weak or negative expression of hDlg had a significantly shorter overall survival rate in comparison with those with a strong or moderate expression in a univariate analysis (p=0.0214; log-rank test). This is the first report to demonstrate that a reduced expression of hDlg protein is an independent negative prognostic factor for MFH.

show abstract

New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma

Cited by 135 publications

References 37 publications

Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3τ and CD44 That Affect Sarcoma Incidence and Survival

Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3τ and CD44 That Affect Sarcoma Incidence and Survival

Liposarcoma retroperitoneal gigante con compromiso renal izquierdo, reporte de un caso en el hospital “San Francisco de Quito”

The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas

Contact Info

Product

Resources

About